Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, PD and Food Effect of HSK44459 in Healthy Subjects
NCT06858657Phase 1Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Aug 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in idiopathic pulmonary fibrosis (IPF), interstitial lung disease (ILD), psoriasis and 2 more comparing HSK44459 with Placebo (2 arms). Primary endpoint: Number and severity of treatment emergent adverse events. Started Aug 2024; status: completed.
02
Drugs
HSK44459
03
Conditions
idiopathic pulmonary fibrosis (IPF)interstitial lung disease (ILD)psoriasisatopic dermatitis (AD)Behcet's disease (BD)
Beyond the preview
Go deeper on NCT06858657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06858657.